FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Elan topics
Folic Acid
Carbon Dioxide
Antibodies
Immune Response
High Energy
Inorganic Compounds
Electrolysis
Semiconductor Material
Semiconductor
Hydrogen Production From Water
Female Sexual Dysfunction
Dysfunction
Sexual Dysfunction
Mammography
Radiograph

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Elan patents



      
           
This page is updated frequently with new Elan-related patent applications. Subscribe to the Elan RSS feed to automatically get the update: related Elan RSS feeds. RSS updates for this page: Elan RSS RSS


Date/App# patent app List of recent Elan-related patents
05/28/15
20150148314
 Seriniquinones, melanoma-specific anticancer agents patent thumbnailnew patent Seriniquinones, melanoma-specific anticancer agents
There are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer.. .
The Regents Of The University Of California, A California Corporation
05/28/15
20150144191
 Polymer sheet patent thumbnailnew patent Polymer sheet
The invention is directed to a polymer sheet and its use as part of a solar paneland glass element. The sheet comprises multiple coextruded polymer layers, wherein at least two or more layers of the polymer sheet comprise a luminescence downshifting compound for at least partially absorbing radiation having a certain wavelength and re-emitting radiation at a longer wavelength than the wavelength of the absorbed radiation, and wherein a luminescence downshifting compound in a first polymer layer can absorb more radiation at a lower wavelength than the luminescence downshifting compound present in a next layer..
Novopolymers N.v
05/21/15
20150141530
 Method and system for predicting recurrence and non-recurrence of melanoma using sentinel lymph node biomarkers patent thumbnailMethod and system for predicting recurrence and non-recurrence of melanoma using sentinel lymph node biomarkers
A method of characterizing melanoma in a subject involves determining the presence or level of one or more bio-markers in a sample obtained from a sentenal lymph node (sln) of a subject.. .
University Of Louisville Research Foundation, Inc.
05/21/15
20150141507
 Melanoma chemoprevention patent thumbnailMelanoma chemoprevention
Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and/or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma, or uv exposure. Sulforaphane can be administered orally as a safe and well-tolerated natural agent as a chemopreventive strategy in individuals with atypical melanocytic nevi..
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
05/21/15
20150141452
 Compositions for affecting weight loss patent thumbnailCompositions for affecting weight loss
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (mc3-r) or a melanocortin 4 receptor (mc4-r) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-msh activity..
Orexigen Therapeutics, Inc.
05/21/15
20150141355
 Salacia compositions, methods of treatment by their administration, and methods of their preparation patent thumbnailSalacia compositions, methods of treatment by their administration, and methods of their preparation
A salacia composition described herein significantly reduces appetite, activates hormone sensitive lipase, and manages a healthy lipid profile through inhibition of hmg-coa reductase enzyme. Salacia compositions described herein include of at least 12% of polyphenols, 2% of mangiferin and 1% of 25,26-oxidofriedelane-1,3-dione by weight of the composition in the form of extract.
Omniactive Health Technologies (canada) Limited
05/21/15
20150140140
 Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care patent thumbnailFormulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care
The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—free-b-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions associated with the skin. This composition of matter simultaneously inhibits cyclooxygenase (cox) and lipoxygenase (lox) enzymatic activity in normal, aged and damaged dermal cells and tissues.
Unigen, Inc.
05/21/15
20150140039
 Immunological markers for adjuvant therapy in melanoma patent thumbnailImmunological markers for adjuvant therapy in melanoma
The present invention concerns embodiments for determining whether an individual in need of immunotherapy will be responsive to the immunotherapy. Determination of one or more snps in particular genes is predictive of responsiveness to immunotherapy, particularly in individuals that have melanoma, for example.
John Wayne Cancer Institute
05/21/15
20150139914
 Contrast-enhancing agent for nuclear magnetic resonance imaging comprising melanin nanoparticles stably dispersed in water patent thumbnailContrast-enhancing agent for nuclear magnetic resonance imaging comprising melanin nanoparticles stably dispersed in water
The present invention relates to a contrast agent for nuclear magnetic resonance imaging, and more particularly, to a contrast agent for nuclear magnetic resonance imaging containing melanin nanoparticles having a uniform shape and size, thereby providing good dispersibility in water, no cell toxicity, and a long retention time in vivo.. .
Research & Business Foundation Sungkyunkwan University
05/14/15
20150133385
 Peptide compounds derived from melanotransferrin and uses thereof patent thumbnailPeptide compounds derived from melanotransferrin and uses thereof
Peptide compounds derived from human melanotransferrin, and compositions thereof, are described. Uses of these peptide compounds, for example to modulate angiogenesis and/or cell migration, and/or to treat angiogenesis-related disorders (e.g., cancer), are also described..
05/14/15
20150133342

Mrm-ms signature assay


The present invention relates to mass spectrometry methods employing multiple reaction monitoring (mrm) in the field of cancer therapeutics, specifically prostate cancer and melanoma.. .
05/14/15
20150132373

Lycopene and resveratrol dietary supplement


A dietary supplement is disclosed comprising lycopene and resveratrol in a range of ratio of lycopene:resveratrol from 1:10 to 10:1. Preferably, the ratio is 1:2 to 1:4.
05/14/15
20150132329

Novel melanoma antigen peptide and uses thereof


The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of seq id no: 10, seq id no: 11, seq id no: 12, seq id no: 13, seq id no: 14 or seq id no: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient..
05/07/15
20150126621

Method for predicting recurrence of melanoma using mirna alterations


Described herein are mirna-based methods for prognosis of recurrence of melanoma and related methods and kits. The present invention addresses these and other needs by providing a method for predicting the likelihood of recurrence of melanoma (including distal metastasis and locoregional recurrence) in a subject diagnosed with melanoma.
New York University
05/07/15
20150126614

Hyaluronic acid production promoter and melanin production inhibitor


A hyaluronic acid production promoter and a melanin synthesis inhibitor include soybean saponin as an active ingredient. The soybean saponin can be a soybean saponin aglycone, such as soyasapogenol a and/or soyasapogenol b.
J-oil Mills, Inc.
05/07/15
20150126533

Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma


Disclosed are methods for the treatment of non-brafv600e mutant melanoma in patients in need of such treatment. The methods comprise administering to such a patient a mek inhibitor such as (r)-3-(2,3-dihydroxypropyl)-6-fluoro-5-((2-fluoro-4-iodophenyl)amino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3h,8h)-dione (tak-733) and a raf inhibitor selected from n-{7-cyano-6-[4-fluoro-3-({[3-(trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (tak-632) and (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (mln2480).
Takeda Pharmaceutical Company Limited
05/07/15
20150126527

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto


The present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal hypertension, hiv infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (pvod) or pulmonary capillary hemangiomatosis (pch); pah with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
05/07/15
20150125559

Method of identifying cosmetic agents for treating periorbital dyschromia and systems therefor


A method of constructing a data architecture for use in identifying connections between perturbagens and genes associated with a type of periorbital dyschromia. The method includes providing a gene expression profile for a keratinocyte, fibroblast, melanocyte or melanoma cell, which has been exposed to at least one perturbagen, and comparing the gene expression profile to a control cell from the same cell line.
The Procter & Gamble Company
05/07/15
20150125466

Methods related to cancer treatment


The present invention relates to method for predicting a subject's relative response to cancer immunotherapy treatment. The methods involve providing a sample comprising a tumor cell or a peripheral blood cell from the subject; measuring the expression level of matrix metalloproteinase-23 (“mmp-23”) by the tumor cell or the peripheral blood cell; comprising the measured expression level of mmp-23 with a control or standard value; and determining the subject's predicted response to cancer immunotherapy, where, based on said comparing, a higher mmp-23 expression level compared to the control or standard value predicts the subject will have a poor response to cancer immunotherapy.
05/07/15
20150125410

Hyaluronic acid production promoter and melanin production inhibitor


A hyaluronic acid production promoter and a melanin synthesis inhibitor include soybean saponin as an active ingredient. The soybean saponin can be a soybean saponin aglycone, such as soyasapogenol a and/or soyasapogenol b.
J-oil, Mills, Inc.
04/30/15
20150119397

Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds.
Quanticel Pharmaceuticals, Inc.
04/30/15
20150119341

Melanocortin-1 receptor-specific linear peptides


Where r1, r2, r3, r4, r5, r6, r7, r8, r9 and r10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.. .
04/30/15
20150118286

Peptide tyrosinase inhibitors and uses thereof


Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Preferred octapeptide sequences are internally rich in tryptophan and/or tyrosine or arginine.
Elixir Institute Of Regenerative Medicine
04/30/15
20150118245

Predictive biomarkers for ctla-4 blockade therapy and for pd-1 blockade therapy


Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irae), or combination thereof for a ctla-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a pd-1 blockade treatment, such as a pd-1 blocking antibody, in a subject with melanoma..
H. Lee Moffitt Cancer Center And Research Institute, Inc.
04/30/15
20150118244

Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients


Provided herein are prognostic and diagnostic methods and kits for use with the methods. For example, provided herein are methods for determining whether a subject having cancer will respond to a cancer treatment.
Bristol-myers Squibb Company
04/30/15
20150118169

Cosmetic compositions and methods


A cosmetic composition for topical application to skin is provided. The cosmetic composition includes vitamin b3 compound, a ricinoleate compound and a dermatologically acceptable carrier.
The Procter & Gamble Company
04/23/15
20150112116

Tyrosine derivatives and compositions comprising them


Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative..
04/23/15
20150111969

J-series prostaglandin-ethanolamides as novel therapeutics


A pharmaceutical composition comprising the compound of formula (i), a pharmaceutical composition comprising anandamide (aea) and methods of using the same in the treatment of non-melanoma skin cancer (nmsc) and colorectal cancer.. .
04/23/15
20150111904

Pharmaceutical combination of mek inhibitor and b-raf inhibitors


A novel combination comprising the mek inhibitor n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or solvate thereof, with a b-raf inhibitor, particularly n-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of mek and/or b-raf is beneficial, eg. Melanoma..
Glaxosmithkline Llc
04/23/15
20150111808

Laundry treatment composition comprising a shading dye and chelant


B. A chelating agent..
04/23/15
20150110725

Mixture for the inhibition of melanin biosynthesis


The present invention relates to a mixture comprising acetylglucosamine and 4-(1-phenylethyl)-1,3-benzenediol for use as a cosmetic and/or medicament, and particularly for the inhibition of melanin biosynthesis, and to a cosmetic and/or pharmaceutical formulation comprising such a mixture for the treatment of hyperpigmented lesions of the skin such as, for example but without limitation, lentigo solaris, age spots, melasma and chloasma, for rendering uniform the color of the skin, for counteracting the formation of free radicals, and for counteracting or preventing signs of skin aging such as wrinkles and lack of skin tone, and generally for improving the aesthetic conditions of the skin.. .
General Topics S.r.l.
04/16/15
20150105251

Composition comprising a biological control agent and a fungicide selected from inhibitors of the lipid membrane synthesis, the melanine biosynthesis, the nucleic acid synthesis or the signal transduction


The present invention relates to a composition comprising at least one biological control agent. Furthermore, the present invention relates to the use of this composition as well as a method for reducing overall damage of plants and plant parts..
Bayer Cropscience Ag
04/09/15
20150099737

Pyrrolopyrimidine compounds as inhibitors of cdk4/6


The invention is directed to novel pyrrolopyrimidine compounds of formula (1) wherein r1, r2y, r4, r8-r11, a and l are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are cdk4/6 inhibitors and could be useful in the treatment of diseases and disorders mediated by cdk4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer.
Novartis Ag
04/09/15
20150098898

Pharmaceutical composition, method and kit for detecting human melanoma cells


The present disclosure is related to a pharmaceutical composition for detecting human melanoma cells, including: a liposome, a biomolecule having specificity for αvβ3 integrin and a radionuclide. The present disclosure also provides a method using the pharmaceutical composition for detecting human melanoma cells and a kit performing the method.
Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan
04/02/15
20150093342

Method to protect skin from ultraviolet radiation using novel peptides involved in the improvement of microparasol organization in keratinocytes


The invention relates to cosmetic methods for improving the microparasol organization in keratinocytes, protecting skin against ultraviolet radiation, decreasing dna photodamage in keratinocytes and melanocytes, attenuating age-related pigmentation defects and the effects of photoaging on the skin. The methods include applying a composition comprising a peptide compound of general formula (i), r1-(aa)n-x1—x2—x3-asp-leu-lys-lys-x4—x5-(aa)p-r2, and a cosmetically acceptable medium..
Isp Investments Inc.
03/26/15
20150087856

Melanin production inhibitor


The present invention provides a melanin production inhibitor containing a compound having a (2-isopropyl-5-methyl)cyclohexyl group or a (2-isopropenyl-5-methyl)cyclohexyl group.. .
Takasago International Corporation
03/26/15
20150087564

Novel enhancing fracture conductivity


Propping compositions comprising: a hardenable, liquid external phase comprising an element selected from the group consisting of: a cement, a cement foam, a polymer, a resin, an aluminum, a flowable carrier fluid, and any combination thereof; and an internal phase that is either gas or liquid and that is immiscible with the external phase; wherein the internal phase exits the propping composition as the hardenable external phase hardens, leaving behind an hardened, interconnected porous network. Some propping compositions may require contact with a treatment for removal from the hardenable external phase and the treatment for removal may comprise at least one material selected from the group consisting of: an acid, a base, a chelant, an oxidizer, a solvent, and any combination thereof..
Halliburton Energy Services, Inc.
03/26/15
20150086615

Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies


Novel sterol derivatives, the preparation method thereof, pharmaceutical compositions containing them and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies. The treatment of glioblastoma multiforme, as well as of other cancers, such as lymphomas, neuroblastomas and melanomas is also described..
Beta Innov
03/26/15
20150086513

Method for deriving melanocytes from the hair follicle outer root sheath and preparation for grafting


The present invention relates to the field of biology and medicine, and more specifically, to the field of stem-cell biology, involving producing or generating melanocytes from stem-cells and precursors derived from human hair root. Additionally, the present invention relates to the materials and method for producing autografts, homografts or allografts comprising melanocytes in general, as well as the materials and methods for producing autografts, homografts and allografts comprising melanocytes for the treatment of diseases related to depigmentation of the skin and for the treatment of scars..
Universitat Leipzig


Popular terms: [SEARCH]

Elan topics: Folic Acid, Carbon Dioxide, Antibodies, Immune Response, High Energy, Inorganic Compounds, Electrolysis, Semiconductor Material, Semiconductor, Hydrogen Production From Water, Female Sexual Dysfunction, Dysfunction, Sexual Dysfunction, Mammography, Radiograph

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Elan for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Elan with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.2095

3137

1 - 1 - 74